Background Little information is available about longterm outcomes of hypofractionated stereotactic radiotherapy (hypo-FSRT) for acoustic neuromas. In this study, the safety and effectiveness of hypo-FSRT for unilateral acoustic neuroma were reviewed over 8 years of experience at our institution. Methods Between May 1998 and October 2006, 27 patients were consecutively treated by linear acceleratorbased hypo-FSRT. Two patients were excluded from this study because they were lost to follow-up within 12 months. The median follow-up period for the rest was 59 (range 24-133) months. Two types of treatment schedules were adopted. Thirteen patients received 30-39 Gy, given in 10-13 fractions (regimen A), whereas after July 2003, 12 patients received 20-24 Gy, given in 5-6 fractions at the tumor periphery (regimen B). These treatments were scheduled to be delivered in three fractions per week (Monday, Wednesday, Friday). The median planning target volume was 2.0, with 1.7 ml (range 0.7-10.6) in regimen A and 5.2 ml (range 0.9-9.3) in regimen B. In the pretreatment audiogram, seven patients (two in regimen A and five in regimen B) had serviceable hearing (Gardner-Robertson Class I-II). Results Local control rates were 100% with regimen A and 92% with regimen B. Serviceable hearing was preserved in four of five patients in regimen B but no patients in regimen A at the last follow-up. No permanent facial or trigeminal nerve morbidity was observed following treatment, and no salvage surgery was needed. Conclusions Hypo-FSRT for acoustic neuromas achieved a high local control rate with minimal facial and trigeminal nerve morbidity.
treatment option for small to large acoustic neuromas, but the morbidity rates cannot be ignored, even with an experienced team [3] . As an alternative, stereotactic radiosurgery (SRS) has been adopted, but initial reports failed to achieve favorable cranial nerve preservation rates. To improve cranial nerve morbidities with a high local control rate, two different radiotherapeutic strategies have been developed; dose-reduced SRS and stereotactic radiotherapy (SRT). Dose-reduced SRS had shown excellent local control rates and minimal morbidity in the treatment of small to medium acoustic neuromas in long-term follow-up [4, 5] . Conventionally, fractionated SRT has also demonstrated high hearing preservation rates and local control over relatively short follow-up periods [6] [7] [8] . Our institution began treating acoustic neuromas with hypofractionated stereotactic radiotherapy (hypo-FSRT) in May 1998. Various schedules of hypofractionation have been developed not only for intracranial but also extracranial lesions [9] [10] [11] . The merits of hypo-FSRT are that it should reduce normal tissue damage compared with SRS and is more convenient than conventionally fractionated SRT because it involves fewer irradiation sessions. Recent studies have reported that hypo-FSRT provides a high local control rate and acceptable morbidity for small and even large acoustic neuromas [12] [13] [14] [15] . However, little information is available as to whether high tumor control rates and minimal morbidity are maintained for an extended period with a hypofractionated regimen. The aim of this study was to review the safety and effectiveness of linear accelerator-based hypo-FSRT for acoustic neuroma over 8 years of experience.
Materials and methods
Between May 1998 and October 2006, 27 patients (27 tumors) with acoustic neuroma underwent hypo-FSRT at Kyoto University Hospital. Two patients who were lost to follow-up within 12 months were excluded from the analysis. For hypo-FSRT, we sought patients with continuously enlarging tumors who were not candidates for surgery. All patients gave informed consent for the treatment. Eleven patients had previously undergone at least one surgical tumor resection and were histologically confirmed to have acoustic neuroma; the median interval between the last surgical procedure and hypo-FSRT was 45 (range 4-120) months. The remaining 14 patients who were diagnosed with acoustic neuroma by imaging studies received hypo-FSRT as an initial treatment. No patient suffered from neurofibromatosis type 2. Patients were regularly followed by physical examination, audiometric testing, and contrastenhanced magnetic resonance (MR) imaging studies every 3-6 months for 3 years and every 12 months thereafter.
All tumors were treated by linear accelerator-based hypo-FSRT using 6 MV X-ray beams generated by a Clinac-2300c linear accelerator (Varian Inc., Palo Alto, CA, USA) with head immobilization using a Gill-ThomasCosman relocatable stereotactic frame. Treatment planning was carried out using the X-knife system (Radionics Inc., Burlington, MA, USA). All patients were treated with a collimating cylinder. From May 1998 to May 2003, 12 patients were treated with a regimen of 39 Gy in 13 fractions at the edge of the planning target volume (PTV) (3.2-3.75 Gy per fraction at the isocenter). One patient was treated with 30 Gy in ten fractions (3.75 Gy per fraction at the isocenter). Starting in July 2003, the regimen was changed by reference to another institutional report [13] , and 11 patients received 20 Gy in five fractions (5 Gy per fraction at the isocenter). One patient was treated with 24 Gy in six fractions (5 Gy per fraction at the isocenter). We defined the regimen of 30-39 Gy in 10-13 fractions as regimen A and 20-24 Gy in 5-6 fractions as regimen B. The median diameter of extrameatal portion was 15 mm: 13 mm (range 5-34) in regimen A and 19 mm (range 5-27) in regimen B. The PTV was defined as the contrastenhancing area of the tumor with a 2-mm margin in helical computed tomography (CT) images of 2.5-mm slice thickness fused with previously generated MR images. The median PTV was 2.0 ml: 1.7 ml (range 0.7-10.6) in regimen A and 5.2 ml (range 0.9-9.3) in regimen B. All patients were treated with a single isocenter, and the collimator diameter ranged from 17.5 to 32.5 mm. Threedimensional multiple arc therapy with a median arc number of five (range 4-7) was used. These treatments were scheduled to be delivered in three fractions per week (Monday, Wednesday, Friday). The median follow-up period was 59 months: 87 (range 24-133) months in regimen A and 39.5 (range 24-64) months in regimen B. Local tumor control was defined as no continuous tumor enlargement on serial MR images. Tumor size was estimated according to the Committee of Hearing and Equilibrium guidelines for the Evaluation of Hearing Preservation in Acoustic Neuroma, in which the diameter of the tumor is defined as the square root of long diameter 9 short diameter [16] . The Gardner-Robertson class system was used to classify hearing [17] (Table 1) . Seven patients with serviceable hearing (Gardner-Robertson class I-II) in the pretreatment audiogram were included for evaluation of hearing preservation. The median pure tone average before hypo-FSRT was 32 dB (range 31-33) in regimen A and 18 dB (range 13-26) in regimen B. The median audiometric follow-up period was 43 (range 30-52) months: 37 (range 30-44) months in regimen A and 43 (range 34-52) months in regimen B. Facial nerve dysfunction was scored using the House-Brackmann grading system [18] ( Table 2 ). The characteristics of 25 patients are outlined in Table 3 .
Results
Local control rates in the follow-up period were 100% (13/13) in regimen A and 92% (11/12) in regimen B. Transient tumor increase was seen in 48% (12/25) of treated tumors but continuous tumor enlargement was observed in the only one case (Fig. 1) . Six tumors, the diameters of the extrameatal portion of which were larger than 25 mm, were well controlled. The median time when the tumor was maximally enlarged after hypo-FSRT was 13 (range 8-35) months. No patient needed salvage surgery within the follow-up period.
Changes of pure tone average after hypo-FSRT in patients with serviceable hearing are shown in Fig. 2 . Deterioration of pure tone average by [20 dB was observed in five of seven patients during the follow-up period. The median pure tone average at the last follow-up was 59.5 dB (range 59-60) in regimen A and 40 dB (range 9-65) in regimen B. Serviceable hearing (GardnerRobertson class I-II) was preserved in four of five patients in regimen B but no patients in regimen A at the last follow-up.
No early toxicity requiring medication occurred. Late toxicity (3 months after hypo-FSRT) requiring treatment was seen in two patients (8%): one with temporary facial paresis (House-Brackmann grade IV) 5 months after the hypo-FSRT in regimen A and one with transient symptomatic noncommunicating hydrocephalus 12 months after hypo-FSRT in regimen B. Facial paresis was resolved within 12 months with orally administered steroid medication. Symptoms related with noncommunicating hydrocephalus disappeared in a month with intravenously administered steroid and glycerol, without permanent cerebrospinal fluid shunting or operative resection of tumor. No patient developed trigeminal nerve dysfunction or dysequilibrium requiring medication in the acute or late period. No radiation-induced secondary tumor was observed.
Discussion
We found that hypo-FSRT for acoustic neuromas had an excellent rate of local control without severe cranial nerve morbidity during his 8-year experience. The findings of this study support the growing body of literature of hypo-FSRT regarding safety and effectiveness. In previous studies, the rate of local control and severe cranial nerve morbidity were reported as 94-100% and 0-3%, respectively [12] [13] [14] [15] (Table 4) , which is comparable with data in our study. In this study, transient enlargement of tumor volume was observed in 48% of treated tumors, but continuous enlargement of tumor volume was observed in only one patient over a follow-up period of 12 months. The reasons for the transitional enlargement remain unclear but are supposed to be associated with intratumoral hemorrhages or increased vascular permeability induced by radiotherapy [19, 20] . The rate of transient tumor enlargement after SRS was reported as 14-45.2% [21] [22] [23] , and the time when the transient enlargement occurred was said to be within 2 years after radiotherapy [21, 22] . Pollock [23] suggested that surgical resection should be delayed until continuous enlargement was confirmed with serial imaging over 2 or more years. In this study, all patients were followed for more than 2 years, and our data was compatible with those reports. Cautious follow-up could be helpful to distinguish transient or progressive enlargement and avoid unnecessary operation due to misinterpretation of natural history of the tumor after radiotherapy. Salvage surgery for an irradiated tumor could cause poor patient outcomes [24, 25] . Hypo-FSRT was effective in controlling tumor growth over a long-term follow-up period. Watch-and-wait policy is important in the follow-up of irradiated acoustic neuromas. Tumor diameter = the diameter of extrameatal portion . Tumor size was estimated using the Committee of Hearing and Equilibrium Guidelines [16] , and the size of the intracanalicular tumor was described as 0 mm. Each regimen included one patient with intracanalicular tumor, which did not enlarge during the follow-up period Six tumors, the diameters of the extrameatal portion of which were [25 mm, were well controlled locally with minimal morbidity in this study. Previously favorable outcomes of radiotherapy for large acoustic neuromas were reported in a short follow-up. Fourteen patients with tumors C3.0 cm received 30 Gy given in ten fractions. No patient had growth of acoustic neuromas or developed facial weakness during the median clinical follow-up of 1.8 years [13] . In another report, tumors C3 cm (16 patients) received 20 Gy in five fractions. All tumors were controlled with median radiographic follow-up of 20 months. No patient developed trigeminal nerve symptoms after treatment, nor did any patient require surgery for treatment failure [26] . In the treatment of large acoustic neuroma, a high local control rate with minimal morbidity was achieved by maximal removal and adjuvant radiotherapy [27, 28] . However, we believe that treatment by radiotherapy alone is still needed for some patients who are unfit for surgery due to medical reasons. This study suggests that radiotherapy alone with hypo-FSRT is one of the acceptable treatment options for large acoustic neuromas.
It is reported that the tendency of deterioration still continued after radiotherapy although the annual rate of hearing loss was decelerated [29, 30] . In this study, continuous hearing deterioration was observed after hypo-FSRT; serviceable hearing was preserved in all patients 1 year after hypo-FSRT but only in four of seven 2 years after hypo-FSRT. Similar deterioration was seen after SRS, and therefore, the rates of hearing preservation were lower in long-term follow-up reports; 44.5% ± 10.5% at 10 years [31] and 55% at 9 years [32] . The wide range of hearing rate preservation from 66% to 100% was reported in hypo-FSRT. Those results may not reflect the change of continuous deterioration of hearing level after radiotherapy because of the relatively short follow-up periods [12] [13] [14] [15] . The length of time required for hearing stabilization after radiotherapy is unclear. Although the amount of literature regarding hypo-FSRT is growing, study follow-up periods are still short. Longer follow-up is required to evaluate hearing rates following hypo-FSRT to reflect the delayed change in hearing level.
Facial nerve preservation and severe trigeminal nerve morbidity rates are reported as 97-100% and 0-3% in hypo-FSRT [12] [13] [14] [15] (Table 4) . Cranial nerve morbidity rates are comparable with those of other radiotherapeutic techniques: gamma knife [31, 33] , linac-based SRS [32, 34] , and conventionally fractionated SRT [8, 35] . The findings in this study substantiate the safety of hypo-FSRT for acoustic neuromas.
Local control rates for small-to medium-sized acoustic neuromas are approaching satisfactory, but hearing preservation rates are not. From the rationale of a linearquadratic model, fractionated SRT is expected to have radiobiological benefits for normal tissue versus SRS. From clinical experience, fractionated SRT led to a higher rate of serviceable hearing preservation than did SRS [7] . Hypo-FSRT has the possibility of being less time consuming than conventionally fractionated SRT and of providing better radiobiological benefit to adjacent normal tissues compared with SRS. Excellent local control with minimal morbidity was demonstrated in this study. However, there were some limitations to the study: it was retrospective in nature; and the study population was heterogeneous with regard to initial treatment, recurrence, tumor size, and hearing ability. Additional studies are needed to evaluate the effectiveness of hypo-FSRT, especially regarding hearing preservation. In conclusion, hypo-FSRT for acoustic neuromas achieved a high local control rate with minimal facial and trigeminal nerve morbidity.
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